Navigo and Mannin agree to develop a novel drug for treating COVID-19
Precision X affinity ligand will enable the efficient purification of the non-Fc fusion protein
Read More
Tag: navigo
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
